Review



pfizer-biontech vaccine series  (BioNTech)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    BioNTech pfizer-biontech vaccine series
    Pfizer Biontech Vaccine Series, supplied by BioNTech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pfizer-biontech+vaccination+series/pm39515133-34-14-14?v=BioNTech
    Average 90 stars, based on 1 article reviews
    pfizer-biontech vaccine series - by Bioz Stars, 2026-07
    90/100 stars

    Images



    Similar Products

    pfizer-biontech vaccine series  (BioNTech)
    90
    BioNTech pfizer-biontech vaccine series
    Pfizer Biontech Vaccine Series, supplied by BioNTech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pfizer-biontech+vaccination+series/pm39515133-34-14-14?v=BioNTech
    Average 90 stars, based on 1 article reviews
    pfizer-biontech vaccine series - by Bioz Stars, 2026-07
    90/100 stars
    		  Buy from Supplier
    pfizer-biontech vaccine series (comirnaty  (BioNTech)
    90
    BioNTech pfizer-biontech vaccine series (comirnaty
    Pfizer Biontech Vaccine Series (Comirnaty, supplied by BioNTech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pfizer-biontech+vaccination+series/pmc10958885-100-5-6?v=BioNTech
    Average 90 stars, based on 1 article reviews
    pfizer-biontech vaccine series (comirnaty - by Bioz Stars, 2026-07
    90/100 stars
    		  Buy from Supplier
    pfizer-biontech covid-19 vaccine primary series  (BioNTech)
    90
    BioNTech pfizer-biontech covid-19 vaccine primary series
    Pfizer Biontech Covid 19 Vaccine Primary Series, supplied by BioNTech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pfizer-biontech+vaccination+series/pmc09949847-103-0-0?v=BioNTech
    Average 90 stars, based on 1 article reviews
    pfizer-biontech covid-19 vaccine primary series - by Bioz Stars, 2026-07
    90/100 stars
    		  Buy from Supplier
    pfizer-biontech covid-19 vaccination series  (BioNTech)
    90
    BioNTech pfizer-biontech covid-19 vaccination series
    Pfizer Biontech Covid 19 Vaccination Series, supplied by BioNTech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pfizer-biontech+vaccination+series/pmc09733849-33-29-29?v=BioNTech
    Average 90 stars, based on 1 article reviews
    pfizer-biontech covid-19 vaccination series - by Bioz Stars, 2026-07
    90/100 stars
    		  Buy from Supplier
    pfizer-biontech vaccination series  (BioNTech)
    90
    BioNTech pfizer-biontech vaccination series
    Characteristics of adverse events reported to the CVMS among children and adolescents aged 5 to 17 years after <t> Pfizer-BioNTech </t> COVID-19 <t> vaccination, </t> Republic of Korea, March 5, 2021 to July 2, 2022
    Pfizer Biontech Vaccination Series, supplied by BioNTech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/pfizer-biontech+vaccination+series/pmc09633262-127-15-15?v=BioNTech
    Average 90 stars, based on 1 article reviews
    pfizer-biontech vaccination series - by Bioz Stars, 2026-07
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Characteristics of adverse events reported to the CVMS among children and adolescents aged 5 to 17 years after Pfizer-BioNTech COVID-19 vaccination, Republic of Korea, March 5, 2021 to July 2, 2022

    Journal: Osong Public Health and Research Perspectives

    Article Title: Adverse events of the Pfizer-BioNTech COVID-19 vaccine in Korean children and adolescents aged 5 to 17 years

    doi: 10.24171/j.phrp.2022.0233

    Figure Lengend Snippet: Characteristics of adverse events reported to the CVMS among children and adolescents aged 5 to 17 years after Pfizer-BioNTech COVID-19 vaccination, Republic of Korea, March 5, 2021 to July 2, 2022

    Article Snippet: From March 5, 2021 to July 2, 2022, in total, 4,995,280 primary doses of the Pfizer-BioNTech vaccination series were administered to children and adolescents aged 5 to 17 years in the ROK, and 14,786 adverse events after vaccination were reported to the CVMS.

    Techniques:

    Types of symptoms and signs reported to the CVMS among children and adolescents aged 5 to 17 years after Pfizer-BioNTech COVID-19 vaccination, Republic of Korea, March 5, 2021 to July 2, 2022

    Journal: Osong Public Health and Research Perspectives

    Article Title: Adverse events of the Pfizer-BioNTech COVID-19 vaccine in Korean children and adolescents aged 5 to 17 years

    doi: 10.24171/j.phrp.2022.0233

    Figure Lengend Snippet: Types of symptoms and signs reported to the CVMS among children and adolescents aged 5 to 17 years after Pfizer-BioNTech COVID-19 vaccination, Republic of Korea, March 5, 2021 to July 2, 2022

    Article Snippet: From March 5, 2021 to July 2, 2022, in total, 4,995,280 primary doses of the Pfizer-BioNTech vaccination series were administered to children and adolescents aged 5 to 17 years in the ROK, and 14,786 adverse events after vaccination were reported to the CVMS.

    Techniques: Injection, Infection, Coagulation

    Characteristics of children and adolescents aged 5 to 17 years who completed at least 1 text message-based survey on days 0 to 7 following Pfizer-BioNTech COVID-19 vaccination, Republic of Korea, December 13, 2021 to June 20, 2022

    Journal: Osong Public Health and Research Perspectives

    Article Title: Adverse events of the Pfizer-BioNTech COVID-19 vaccine in Korean children and adolescents aged 5 to 17 years

    doi: 10.24171/j.phrp.2022.0233

    Figure Lengend Snippet: Characteristics of children and adolescents aged 5 to 17 years who completed at least 1 text message-based survey on days 0 to 7 following Pfizer-BioNTech COVID-19 vaccination, Republic of Korea, December 13, 2021 to June 20, 2022

    Article Snippet: From March 5, 2021 to July 2, 2022, in total, 4,995,280 primary doses of the Pfizer-BioNTech vaccination series were administered to children and adolescents aged 5 to 17 years in the ROK, and 14,786 adverse events after vaccination were reported to the CVMS.

    Techniques:

    Adverse events and health conditions reported among children and adolescents aged 5 to 17 years following Pfizer-BioNTech coronavirus disease 2019 vaccination, Republic of Korea, December 13, 2021 to June 20, 2022. Values represent the percentage of respondents who reported adverse events and health conditions at least once during days 0 to 7 post-vaccination. (A) Dose 1. (B) Dose 2. 5–11 y, children aged 5–11 years; 12–17 y, adolescents aged 12–17 years.

    Journal: Osong Public Health and Research Perspectives

    Article Title: Adverse events of the Pfizer-BioNTech COVID-19 vaccine in Korean children and adolescents aged 5 to 17 years

    doi: 10.24171/j.phrp.2022.0233

    Figure Lengend Snippet: Adverse events and health conditions reported among children and adolescents aged 5 to 17 years following Pfizer-BioNTech coronavirus disease 2019 vaccination, Republic of Korea, December 13, 2021 to June 20, 2022. Values represent the percentage of respondents who reported adverse events and health conditions at least once during days 0 to 7 post-vaccination. (A) Dose 1. (B) Dose 2. 5–11 y, children aged 5–11 years; 12–17 y, adolescents aged 12–17 years.

    Article Snippet: From March 5, 2021 to July 2, 2022, in total, 4,995,280 primary doses of the Pfizer-BioNTech vaccination series were administered to children and adolescents aged 5 to 17 years in the ROK, and 14,786 adverse events after vaccination were reported to the CVMS.

    Techniques:

    Adverse events and health conditions reported among children and adolescents aged 5 to 17 years following Pfizer-BioNTech COVID-19 vaccination, Republic of Korea, December 13, 2021 to June 20, 2022

    Journal: Osong Public Health and Research Perspectives

    Article Title: Adverse events of the Pfizer-BioNTech COVID-19 vaccine in Korean children and adolescents aged 5 to 17 years

    doi: 10.24171/j.phrp.2022.0233

    Figure Lengend Snippet: Adverse events and health conditions reported among children and adolescents aged 5 to 17 years following Pfizer-BioNTech COVID-19 vaccination, Republic of Korea, December 13, 2021 to June 20, 2022

    Article Snippet: From March 5, 2021 to July 2, 2022, in total, 4,995,280 primary doses of the Pfizer-BioNTech vaccination series were administered to children and adolescents aged 5 to 17 years in the ROK, and 14,786 adverse events after vaccination were reported to the CVMS.

    Techniques: